NTLA Stock Recent News
NTLA LATEST HEADLINES
The average analyst following Ginkgo Bioworks thinks the stock can climb 140% from recent prices over the next 12 months or so. The consensus price target on Intellia Therapeutics suggests it can more than triple your money from recent prices.
Intellia Therapeutics has a promising candidate about to enter late-stage testing. The company has a couple of exciting earlier-stage programs, too.
Intellia Therapeutics is well capitalized, and moving into late-stage clinical trials. CRISPR Therapeutics will be raking in revenue and likely launching another therapy.
Intellia Therapeutics (NTLA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Intellia Therapeutics (NASDAQ: NTLA ) layoffs are a hot topic on Friday as the company prepares to cut jobs following an internal strategic review. According to a press release from Intellia Therapeutics, the company is reducing its total headcount by 15% to streamline operations.
Gene editing stocks have received a lot of attention throughout 2023. The intense focus on gene editing therapies and CRISPR technology is likely only to increase moving forward: The U.S. Food and Drug Administration (FDA) just approved the world's first medicine employing CRISPR technology.
Intellia and CRISPR Therapeutics both work in the field of gene editing. CRISPR Therapeutics just won regulatory approval for its first product, while Intellia recently entered late-stage development with its lead candidate.
Intellia Therapeutics and CRISPR Therapeutics are considered the top two players in the CRISPR space in the next 1 to 3 years. NTLA focuses on in vivo gene editing and has a comprehensive pipeline targeting various genetic diseases and conditions. CRSP focuses on ex vivo gene editing and has a diverse pipeline targeting different therapeutic areas, including hemoglobinopathies, immuno-oncology, and regenerative medicine.
Teladoc Health is roaring ahead on the path to profitability, making gains in EBITDA and free cash flow. One of Intellia Therapeutics' gene-editing candidates is entering late-stage studies, a step closer to product commercialization.
The European Commission bestows orphan drug designation to Intellia's (NTLA) in vivo CRISPR-based investigational therapy, NTLA-2002, for treating hereditary angioedema. Stock rises.